<DOC>
	<DOCNO>NCT00671307</DOCNO>
	<brief_summary>This study design assess pharmacokinetics safety infusion single dose recombinant plasma gelsolin ( rhu-pGelsolin ) give patient admit Intensive Care Unit document low level natural gelsolin . It believe drug raise gelsolin level patient decrease probability develop complication underlie disease organ system failure death .</brief_summary>
	<brief_title>Ascending Single Dose Study Rhu-pGelsolin Patients With Decreased Gelsolin Levels</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , ascend single dose rhu-pGelsolin infusion study . Thirteen subject ( 10 active 3 placebo ) dose 3 mg/kg 5 subject ( 3 active 2 placebo ) dose 6 mg/kg . In addition , twenty-two subject ( 18 active 4 placebo ) dose 6 mg/kg per day 3 day . The Data Safety Monitoring Committee ( DSMC ) Steering Committee review precede dose safety data , agree tolerability prior enrolment next high dose . Blood sample collect 1 hour infusion 72 hour post dose PK assessment dose .</detailed_description>
	<criteria>&gt; 18 year age Documented gelsolin level &lt; 100 mg/mL Admission ICU Women childbearing age negative pregnancy test Multiple Organ Failure score &lt; 4 Catheter present blood sample take Written Informed Consent obtain Participation investigational treatment protocol Patients &lt; 18 year age Patients modify Multiple Organ Failure score &gt; =4 Patient , opinion Principal Investigator , unlikely ICU &gt; 48 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Gelsolin</keyword>
	<keyword>Trauma</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Peritonitis</keyword>
	<keyword>Burn</keyword>
	<keyword>Infection</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
</DOC>